Irl Hirsch Reviews ADA Highlights With Anne Peters

COMMENTARY

Irl Hirsch Reviews ADA Highlights With Anne Peters

Anne L. Peters, MD; Irl B. Hirsch, MD; Mark Harmel, MPH

Disclosures

July 01, 2020

1

Irl Hirsch Reviews ADA Highlights With Anne Peters
Irl Hirsch Reviews ADA Highlights With Anne Peters
00:00
00:0010:46GO LIVE

This transcript has been edited for clarity.

Anne L. Peters, MD: I'm here with a dear friend of mine, Dr Irl Hirsch, at the end of the virtual American Diabetes Association (ADA) Scientific Sessions to discuss a few of the findings from the meeting, as well as how we feel about virtual meetings. Irl, could you tell us a bit about some of the newer insulins?

Irl B. Hirsch, MD: Yes, thank you. It's always good to be with you. There are, as usual, quite a few new insulins to think about and hope come to the market. One of those is the weekly long-acting basal insulin from Novo Nordisk. I did not know this was in development. What's interesting is that other companies are also working on a weekly basal insulin.

Upon my first glance at the data, I think this will work quite well in people with type 2 diabetes. We now have history of using a weekly medication in type 2 diabetes with our GLP-1 inhibitors.

But I am a bit concerned about using a weekly insulin because of the fact that the half-life of this insulin is 196 hours. That's incredible. Think about onboarding patients on the outpatient side, but even more so — and this has become a big interest of mine — what happens when somebody on a weekly basal insulin comes in to the hospital and that insulin is not in the hospital?

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....